Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Pro-proliferative FoxM1 is a target of p53-mediated repression.

Barsotti AM, Prives C.

Oncogene. 2009 Dec 3;28(48):4295-305. doi: 10.1038/onc.2009.282.

2.

p53 negatively regulates expression of FoxM1.

Pandit B, Halasi M, Gartel AL.

Cell Cycle. 2009 Oct 15;8(20):3425-7.

PMID:
19806025
3.

ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.

Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, Hajji N, Lam EW.

Mol Cancer Ther. 2011 Jun;10(6):1046-58. doi: 10.1158/1535-7163.MCT-11-0024.

4.

Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner.

Baptiste-Okoh N, Barsotti AM, Prives C.

Cell Cycle. 2008 May 1;7(9):1133-8.

PMID:
18418048
5.

p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2.

Jackson MW, Agarwal MK, Yang J, Bruss P, Uchiumi T, Agarwal ML, Stark GR, Taylor WR.

J Cell Sci. 2005 May 1;118(Pt 9):1821-32.

6.

Two-fold elevation of expression of FoxM1 transcription factor in mouse embryonic fibroblasts enhances cell cycle checkpoint activity by stimulating p21 and Chk1 transcription.

Tan Y, Chen Y, Yu L, Zhu H, Meng X, Huang X, Meng L, Ding M, Wang Z, Shan L.

Cell Prolif. 2010 Oct;43(5):494-504. doi: 10.1111/j.1365-2184.2010.00699.x.

PMID:
20887555
8.
9.

Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1.

Penzo M, Massa PE, Olivotto E, Bianchi F, Borzi RM, Hanidu A, Li X, Li J, Marcu KB.

J Cell Physiol. 2009 Jan;218(1):215-27. doi: 10.1002/jcp.21596. Erratum in: J Cell Physiol. 2010 Aug;224(2):566.

10.

Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma.

Qu K, Xu X, Liu C, Wu Q, Wei J, Meng F, Zhou L, Wang Z, Lei L, Liu P.

Cancer Lett. 2013 Apr 30;331(1):105-14. doi: 10.1016/j.canlet.2012.12.008.

PMID:
23262037
11.

p53-dependent down-regulation of telomerase is mediated by p21waf1.

Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V.

J Biol Chem. 2004 Dec 3;279(49):50976-85.

12.
13.

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.

Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR.

Oncotarget. 2015 Sep 29;6(29):27613-27. doi: 10.18632/oncotarget.4546.

14.

TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.

Madan E, Gogna R, Kuppusamy P, Bhatt M, Pati U, Mahdi AA.

Br J Cancer. 2012 Jul 24;107(3):516-26. doi: 10.1038/bjc.2012.260.

15.

Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.

Zhang X, Cheng L, Minn K, Madan R, Godwin AK, Shridhar V, Chien J.

Oncotarget. 2014 Nov 30;5(22):11365-80.

16.

Mdm2 inhibition of p53 induces E2F1 transactivation via p21.

Wunderlich M, Berberich SJ.

Oncogene. 2002 Jun 27;21(28):4414-21.

17.

Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1.

Liu X, Cai W, Niu M, Chong Y, Liu H, Hu W, Wang D, Gao S, Shi Q, Hu J, Zhou X, Yu R.

J Neurooncol. 2015 Feb;121(3):469-77. doi: 10.1007/s11060-014-1664-2.

PMID:
25528634
18.

E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.

Li Y, Shao J, Shen K, Xu Y, Liu J, Qian X.

J Cell Biochem. 2012 Oct;113(10):3165-77. doi: 10.1002/jcb.24194.

PMID:
22593008
19.

Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression.

Zhang M, Liu Y, Gao Y, Li S.

Eur J Pharmacol. 2015 Oct 15;765:346-54. doi: 10.1016/j.ejphar.2015.08.057.

PMID:
26342429
20.

Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.

Wang Z, Zheng Y, Park HJ, Li J, Carr JR, Chen YJ, Kiefer MM, Kopanja D, Bagchi S, Tyner AL, Raychaudhuri P.

Mol Cancer Ther. 2013 May;12(5):759-67. doi: 10.1158/1535-7163.MCT-12-0903.

Items per page

Supplemental Content

Support Center